Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02917187 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
A Phase 2 study of Primary Inherited Erythromelalgia, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 5
- Study locations
NCT02917187 is a Phase 2 study of Primary Inherited Erythromelalgia that has completed, run by Biogen. The registered enrollment target is 8 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT02917187, a Phase 2 study of Primary Inherited Erythromelalgia, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on paroxysmal pain in participants with Primary Inherited Erythromelalgia (EM). The secondary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on varying additional aspects of pain in participants with EM; and to investigate the safety and tolerability of repeat oral dosing of BIIB074 in participants with EM.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BIIB074
Study Locations (5)
Alabama
- Research Site - Birmingham
Connecticut
- Research SIte - New London
Pennsylvania
- Research Site - Philadelphia
Texas
- Research Site - Plano
West Virginia
- Research Site - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-09-09 |
| Est. Completion | 2017-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02917187
The ClinicalTrials.gov registry entry for NCT02917187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Inherited Erythromelalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02917187 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Connecticut, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02917187 about?
NCT02917187 is a clinical study titled "A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia". The primary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on paroxysmal pain in participants with Primary Inherited Erythromelalgia (EM). The secondary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on varying additiona...
What is the current status of trial NCT02917187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-09-09. Estimated completion is 2017-01-05.
What conditions does trial NCT02917187 study?
This clinical trial studies the following conditions: Primary Inherited Erythromelalgia.
What interventions are being tested in trial NCT02917187?
The interventions under investigation include: Placebo (DRUG), BIIB074 (DRUG).
Who is sponsoring clinical trial NCT02917187?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02917187 being conducted?
This trial has 5 study locations across Alabama, Connecticut, Pennsylvania, Texas, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.